Pharmacology, Toxicology and Pharmaceutical Science
Active Pharmaceutical Ingredient
49%
Adenosine
31%
Adverse Event
28%
Albumin
34%
Bioavailability
36%
Biocompatibility
48%
Biopharmaceutical
70%
Cell Culture
43%
Chitosan
47%
Chronic Obstructive Lung Disease
27%
Cysteine
31%
Darunavir
31%
Diseases
30%
Drug Absorption
73%
Drug Delivery Device
31%
Drug Release
27%
Drug Transport
31%
Dry Powder Inhaler
39%
Effusion
42%
Excipient
48%
Fluticasone
31%
Fluticasone Propionate
58%
Hyaluronic Acid
39%
Hydrogen Peroxide
31%
Hydrophobicity
47%
Inflammation
38%
Lactose
65%
Lung Disease
35%
Macrogol
35%
Mannitol
34%
Naloxone
31%
Nanocapsule
37%
Nanoparticle
100%
Normal Human
30%
P-Glycoprotein
63%
Particle Deposition
34%
Penetration Enhancing Agent
31%
Pharmaceutical Aerosols
35%
Pharmaceutics
61%
Pharmacokinetic
75%
Polyvinyl Acetate
27%
Psilocybin
31%
Respiratory Tract
42%
Salbutamol Sulfate
29%
Salmeterol Xinafoate
47%
Tablet
50%
Thioglycolic Acid
28%
Toxicology
27%
Treatment Resistant Depression
31%
Unspecific Monooxygenase
31%
Medicine and Dentistry
16HBE14o- Cell Line
10%
4 Hydroxybenzoic Acid
5%
Adenosine
15%
Adverse Event
5%
Airway Cell
15%
Allergen
15%
Awareness
15%
Bioequivalence
5%
Biopharmaceuticals
7%
Bronchoconstriction
15%
Caco-2
6%
Cell Culture
7%
Cell Line
7%
Collagen Type 1
7%
Copper Oxide Nanoparticle
15%
Cystic Fibrosis
31%
Depressive Disorder
15%
Drug Absorption
18%
Drug Activity
7%
Drug Administration
7%
Drug Penetration
15%
Drug Transport
15%
Endotoxin
15%
Epithelial Cell
7%
Epithelial Cell Line
18%
Feeding
7%
In Vitro
31%
In Vitro In Vivo Correlation
5%
Lung
63%
Mannitol
23%
Medicine
5%
Methacholine
15%
Microbial Diversity
15%
Naloxone
15%
Obstructive Lung Disease
15%
Open-Label Trial
5%
Patient with Cystic Fibrosis
19%
Psilocybine
31%
Psychotomimetic
7%
Respiratory Drug Transport
7%
Respiratory Medicine
15%
Restriction Fragment Length Polymorphism
9%
Sputum
6%
Systematic Review
15%
Treatment Resistant Depression
31%
